目的 探讨肿瘤标志物联合MRI诊 断子宫颈癌的临床价值。方法 收集2012 年4月-2015年6月我院收治的78例子宫颈 癌患者为研究组，选取同期来我院体检 的40例健康人作为对照组，入院后均采 集空腹静脉血，测定肿瘤标志物鳞状细胞 癌抗原(SCCA)、糖类抗原153(CA153)、 糖类抗原125(CA125)、细胞角蛋白21- 1(CYFRA211)水平，同时所有患者均给予 MRI检查，以病理活检结果为金标准，分 析肿瘤标志物、MRI及其联合诊断对宫颈 癌的临床价值。结果 研究组血清SCCA、 CA125、CA153、CYFRA211水平均高于对照 组(P<0.05)；宫颈癌灶组织ARSI %高于正 常组织(P<0.05)，两者MRSI %对比差异 无统计学意义(P>0.05)；MRI诊断宫颈癌 阳性率为96.15 %，高于肿瘤标志物各项 (P<0.05)，肿瘤标志物联合MRI诊断宫颈 癌准确率高于MRI，但对比差异无统计学 意义(P>0.05)。结论 子宫颈癌患者血清 SCCA、CA125、CA153、CYFRA211明显上 调，其中CA125敏感度最高，但肿瘤标志 物筛查阳性率低于MRI，可将MRI作为宫颈 癌筛查的首选手段，将肿瘤标志物作为辅 助手段。

Objective To investigate the clinical value of tumor markers combined with MRI in the diagnosis of cervical cancer. Methods Seventy-eight cases of patients with cervical cancer who were admitted to our hospital between April 2012 and June 2015 were enrolled in the study group, and 40 healthy persons were selected as control group at the same time. After admission, the fasting venous blood was collected. The levels of tumor markers squamous cell carcinoma antigen (SCCA), carbohydrate antigen 153 (CA153), carbohydrate antigen 125 (CA125), cytokeratin 21-1 (CYFRA211)] were determined. Meanwhile, all patients underwent MRI examination. With the results of pathological biopsy results as the golden standard, the clinical value of tumor markers, MRI and their combined diagnosis of cervical cancer was analyzed. Results The levels of serum SCCA, CA125, CA153 and CYFRA211 in the study group were higher than those in the control group (P<0.05). ARSI% of cervical cancer was higher than that of normal tissues (P<0.05), and there was no significant difference between the two groups in MRSI% (P>0.05). The positive rate of cervical cancer diagnosed by MRI (96.15%) was higher than that by tumor markers (P<0.05). The accuracy of tumor markers combined with MRI in the diagnosis of cervical cancer was higher than that of MRI, but there was no significant difference (P>0.05). Conclusion The levels of serum SCCA, CA125, CA153 and CYFRA21-1 in patients with cervical cancer are significantly higher, and CA125 is the most sensitive, but screening positive rate of tumor markers is lower than MRI. MRI can be used as an preferred means of screening for cervical cancer, and tumor markers can be taken as an adjuvant means.